A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This clinical trial is being conducted to determine tumor response and preliminary safety of
a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that
is required for the establishment of new blood vessels during tumor growth, a process known
as angiogenesis.